Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
33.70
-3.41 (-9.19%)
Apr 3, 2025, 11:33 AM EDT - Market open

Company Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide.

It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050.

In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100.

It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.
Praxis Precision Medicines logo
Country United States
Founded 2015
IPO Date Oct 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 116
CEO Marcio De'Souza

Contact Details

Address:
99 High Street, 30th Floor
Boston, Massachusetts 02110
United States
Phone 617 300 8460
Website praxismedicines.com

Stock Details

Ticker Symbol PRAX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001689548
CUSIP Number 74006W108
ISIN Number US74006W2070
SIC Code 2834

Key Executives

Name Position
Marcio Silva De'Souza M.B.A. President, Chief Executive Officer and Director
Timothy Edwin Kelly Chief Financial Officer and Treasurer
Alex Nemiroff J.D. General Counsel and Secretary
Dr. Steven Petrou B.Sc. (Hons.), Ph.D. Co-Founder and Chief Scientific Officer
Lauren Mastrocola Vice President of Finance and Principal Accounting Officer
Dr. Karl Hansen Ph.D. Chief Technical Operations Officer
Alex Kane Vice President of Investor Relations and Corporate Communications
Kelly McCue Chief People Officer
Alyssa J. S. Wyant Chief Regulatory and Quality Officer
Megan T. Sniecinski Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 19, 2025 SCHEDULE 13G Filing
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2025 10-K Annual Report
Feb 28, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 SCHEDULE 13G Filing